ADVERTISEMENT
ADVERTISEMENT

Regulatory T cells take the spotlight

Credit: © STEVE GSCHMEISSNER/PHOTO RESEARCHERS, INC" /> Credit: © STEVE GSCHMEISSNER/PHOTO RESEARCHERS, INC It?s a constant nagging problem, how cancers loaded with mutant proteins escape immune response. In 2004, Weiping Zou, now at the University of Michigan School of Medicine in Ann Arbor, and his colleagues showed that human ovarian tumors can recruit regulatory T cells to suppress other T cells.1 They do this by generating large amounts of the chemokine CCL22. Their findings poi

Charles Q. Choi
<figcaption> Credit: © STEVE GSCHMEISSNER/PHOTO RESEARCHERS, INC</figcaption>
Credit: © STEVE GSCHMEISSNER/PHOTO RESEARCHERS, INC

It?s a constant nagging problem, how cancers loaded with mutant proteins escape immune response. In 2004, Weiping Zou, now at the University of Michigan School of Medicine in Ann Arbor, and his colleagues showed that human ovarian tumors can recruit regulatory T cells to suppress other T cells.1 They do this by generating large amounts of the chemokine CCL22. Their findings pointed to a significant link between regulatory T-cell levels and patient mortality.

The paper remains "the best study of regulatory T cells in a human tumor system," Yang-Xin Fu at the University of Chicago says. In addition to revealing a novel and important mechanism tumors use to suppress the immune system, Ping Yu at the University of Chicago says it revealed a new cancer therapy strategy. In mice bearing human tumors, Zou and his colleagues found that antibodies targeting CCL22 blocked migration...

1. T.J. Curiel et al., "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival." Nat Med, 10:942?9, 2004. (Cited in 207 papers)

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT